3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 3
1
Status
Recruiting
3
Withdrawn
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
OTHER
1
Study Type
Interventional
3
Sponsor
Cancer Type
Genitourinary
2
Endocrine
2
CNS
2
Conditions
Carcinoma, Renal Cell
8
von Hippel-Lindau Disease
3
Pheochromocytoma
2
Paraganglioma
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Ovarian Neoplasms
1
Neuroectodermal Tumors, Primitive
1
Neoplasm Metastasis
1
Metastatic Castration-Resistant Prostate Cancer
1
Kidney Neoplasms
1
Hemangioblastoma
1
Endometrial Neoplasms
1
Clear-cell metastatic renal cell carcinoma
1
Carcinoma
1
Breast Neoplasms
1
Adenoma, Islet Cell
1
Interventions
belzutifan
3
palbociclib
1
lenvatinib
1
gallium Ga 68 dotatate
1
cabozantinib
1
Propranolol
1
Nivolumab
1
Everolimus
1
Blood Specimen Collection
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Recruiting
×
von Hippel-Lindau Disease
×
belzutifan
×
Clear all
NCT07405164
2026-05-29
MK-6482-043
Merck Sharp & Dohme LLC
Phase 3
Recruiting
450 enrolled
NCT04924075
2026-05-28
MK-6482-015
Merck Sharp & Dohme LLC
Phase 2
Recruiting
322 enrolled
1 FDA
NCT07167329
2025-09-11
BELIEVE-VHL
AC Camargo Cancer Center
Phase 2
Recruiting
100 enrolled